Hims&Hers Health declines as Lilly launches single-dose vials of Zepbound
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
Deutsche Bank on Eli Lilly (LLY): 'Zep Going (Lilly) Direct to Vials Helps Bridge GLP-1 Supply/Demand'
August 27, 2024 10:26 AM EDTDeutsche Bank analyst James Shin reiterated a Buy rating and $1,025.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "As noted on their 2Q24 call, LLY this AM formally stated Zepbound vials (2.5mg and 5.0mg) will be available via LillyDirect's self-pay channel. Monthly... More
